Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PORT-5
- Development stage
- Preclinical
- Lead developer
- AlphaTON Capital
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
PORT-5 is a preclinical virus-like drug conjugate (VDC) designed as a small-molecule or conjugated modulator of the stimulator of interferon genes (STING) pathway, initially developed by AlphaTON Capital and further advanced by Portage Biotech for oncology indications such as solid tumors. By modulating STING, a central cytosolic DNA sensor that drives type I interferon and pro‑inflammatory cytokine production, PORT-5 is intended to enhance innate immune activation within the tumor microenvironment and promote anti-tumor immunity. As a VDC, the agent is engineered for targeted delivery and improved pharmacologic properties relative to unconjugated STING agonists, with development currently at the preclinical stage.[1]
- Other names
- STING-VLP
02
Targets
STING (Stimulator of interferon genes protein)
Beyond the preview
Go deeper on PORT-5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PORT-5.